Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
China Medical System Holdings ( (HK:0867) ) has provided an announcement.
China Medical System Holdings announced that its dermatology-focused subsidiary Dermavon has received approval from China’s National Medical Products Administration for ruxolitinib phosphate cream to treat non-segmental vitiligo with facial involvement in patients aged 12 and above, making it the first and only targeted therapy for vitiligo approved in the country. The product, already marketed overseas as Opzelura for vitiligo and certain atopic dermatitis indications, addresses a major unmet need among an estimated 8.2 million non-segmental vitiligo patients in China, where existing treatments such as topical corticosteroids and calcineurin inhibitors have significant limitations.
Before full approval, the cream had already been used under special pilot access policies in Hainan’s Lecheng Pilot Zone and certain free trade zones, with more than 7,000 Chinese patients treated and prescriptions available at over 20 hospitals in major cities. Clinical data from two Phase III overseas trials and real-world Chinese studies showed significantly higher repigmentation rates versus placebo, sustained benefit with longer use, and no new safety issues, positioning the drug as a landmark addition to vitiligo care and strengthening Dermavon’s skin treatment portfolio as it moves toward a separate market listing.
The most recent analyst rating on (HK:0867) stock is a Hold with a HK$14.50 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
More about China Medical System Holdings
China Medical System Holdings is a pharmaceutical group with a focus on innovative therapies, operating through subsidiaries such as Dermavon Holdings, which specializes in skin health. Dermavon is in the process of seeking a separate listing on the Main Board of the Hong Kong Stock Exchange, highlighting the Group’s strategy to build a dedicated dermatology platform and expand its footprint in the medical skin treatment market.
Average Trading Volume: 4,463,748
Technical Sentiment Signal: Buy
Current Market Cap: HK$33.67B
See more insights into 0867 stock on TipRanks’ Stock Analysis page.